Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

In updated data for molnupiravir, Merck's covid-19 pill, the company has said that the drug was significantly less effective in cutting hospitalizations and deaths earlier analysis has reported.
Merck & Co said its pill showed a 30% reduction in hospitalizations and deaths, based on data from 1,433 patients. Earlier in October, it showed a roughly 50% efficacy, based on data from 775 patients.
Also watch | Britain clears Merck's pill to treat Covid-19: here's all you need to know about molnupiravir
The lower efficacy of Merck’s drug could have big implications in terms of whether countries will buy and roll the usage of the pill. 
The current data will be presented at the centre of a panel discussion by US Food and Drug Administration advisers regarding its use to treat Covid in high-risk patients.

 Merck's pill to treat Covid-19 significantly less effective in new analysis

Merck & Co said updated results showed its Covid-19 pill reduced the risk of hospitalization or death among adults with mild to moderate disease by 30%.

In updated data for molnupiravir, Merck's covid-19 pill, the company has said that the drug was significantly less effective in cutting hospitalizations and deaths earlier analysis has reported.
Merck &amp; Co said its pill showed a 30% reduction in hospitalizations and deaths, based on data from 1,433 patients. Earlier in October, it showed a roughly 50% efficacy, based on data from 775 patients.
The lower efficacy of Merck&rsquo;s drug could have big implications in terms of whether countries will buy and roll the usage of the pill.
The current data will be presented at the centre of a panel discussion by US Food and Drug Administration advisers regarding its use to treat Covid in high-risk patients.

The lower efficacy of Merck&rsquo;s drug could have big implications in terms of whether countries will buy and roll the usage of the pill.

In updated data for molnupiravir, Merck's Covid-19 pill, the US pharma&nbsp;giant&nbsp;has said that the drug was significantly less effective in cutting hospitalizations and deaths earlier analysis has reported.
Merck said its pill showed a 30% reduction in hospitalizations and deaths, based on data from 1,433 patients. Earlier in October, it showed a roughly 50% efficacy, based on data from 775 patients.
Also watch | <a href="https://www.editorji.com/world-news/britain-clears-merck-s-pill-to-treat-covid-19-here-s-all-you-need-to-know-about-molnupiravir-1636029679595" target="_blank">Britain</a><a href="https://www.editorji.com/world-news/britain-clears-merck-s-pill-to-treat-covid-19-here-s-all-you-need-to-know-about-molnupiravir-1636029679595" target="_blank"> clears Merck's pill to treat Covid-19: here's all you need to know about molnupiravir</a>
The lower efficacy of Merck&rsquo;s drug could have big implications in terms of whether countries will buy and roll the usage of the pill.
The current data will be presented at the centre of a panel discussion by US Food and Drug Administration advisers regarding its use to treat Covid in high-risk patients.

anti covid pills

Categories